Six-Month Strategy Holds Up in Rifampicin-Resistant TB
A randomized South African trial supports six-month treatment for eligible rifampicin-resistant tuberculosis, potentially reducing treatment burden while requiring careful regimen selection and safety monitoring.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.